Two Stage Design [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2008-08-28 13:50 (6081 d 19:45 ago) – Posting: # 2270
Views: 23,830

Dear JPL!

❝ I don't have access to the paper, but it is an interesting issue.


You should get it for about 30 USD - it’s worth it and really quite nice to read. The study which formed the basis of the publication was performed by the ‘The Product Quality Research Institute’ (PQRI) which is a non-profit organization founded in 1999. Members amongst others are FDA-CDER, Health Canada, USP, AAPS, PhRMA. A working group on sequential designs in BE was founded in 2003. They are really heavy weights (definitely not some obscure back-yard statisticians).
Each of the four methods was tested in 1 million (!) of simulated BE studies, with the exception of method A – which is even more strict than a simple add-on design (because it contained a stop criterion if in the first part power >80%). Method A was not considered further, because the alpha-risk was inflated.

❝ But what is meant by "evaluate the power at stage 1"?


This is just the validated decision procedure between the branches.

❝ Am I right that only sample size is adjusted, but intial assumptions on difference and variance are used otherwise?


Essentially the sample size is updated only based on the variance of part 1. Although in adaptive designs it’s possible to update the sample size both on a new estimate of CV and the size of the effect (in the BE setting the ratio T/R), only the former was studied and validated in the study; the latter is considered to be evaluated by the group.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
23 visitors (0 registered, 23 guests [including 4 identified bots]).
Forum time: 09:36 CEST (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5